128 related articles for article (PubMed ID: 36941031)
1. Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy.
Alonso N; Albagha OME; Azfer A; Larraz-Prieto B; Berg K; Riches PL; Ostanek B; Kocjan T; Marc J; Langdahl BL; Ralston SH
Ann Rheum Dis; 2023 Jul; 82(7):985-991. PubMed ID: 36941031
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis.
Mochizuki T; Yano K; Ikari K; Okazaki K
J Bone Miner Metab; 2023 Mar; 41(2):220-226. PubMed ID: 36625920
[TBL] [Abstract][Full Text] [Related]
4. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
5. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs.
Song J; Jin Z; Chang F; Li L; Su Y
Med Sci Monit; 2014 Dec; 20():2624-32. PubMed ID: 25503108
[TBL] [Abstract][Full Text] [Related]
6. Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.
Kong M; Gao C; Luan X; Fan C; Hao M; Jin C; Zhao J; Li H; Zhao J; Luan J; Lin Y; Li Q
BMC Musculoskelet Disord; 2024 Feb; 25(1):109. PubMed ID: 38310278
[TBL] [Abstract][Full Text] [Related]
7. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
[TBL] [Abstract][Full Text] [Related]
8. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
9. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
10. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
[TBL] [Abstract][Full Text] [Related]
11. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
[TBL] [Abstract][Full Text] [Related]
13. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
Takeuchi Y; Kuroda T; Sugimoto T; Shiraki M; Nakamura T
Calcif Tissue Int; 2016 Feb; 98(2):186-92. PubMed ID: 26478225
[TBL] [Abstract][Full Text] [Related]
14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
15. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
16. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
Cohen A; Kamanda-Kosseh M; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; Bucovsky M; Stubby J; Shane E
J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
[TBL] [Abstract][Full Text] [Related]
17. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.
Lee S; Hong N; Kim KJ; Park CH; Lee J; Rhee Y
Calcif Tissue Int; 2021 Nov; 109(5):544-553. PubMed ID: 34037833
[TBL] [Abstract][Full Text] [Related]
18. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
19. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.
Leder BZ; Neer RM; Wyland JJ; Lee HW; Burnett-Bowie SM; Finkelstein JS
J Clin Endocrinol Metab; 2009 Aug; 94(8):2915-21. PubMed ID: 19435827
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
